A next-generation Duchenne drug?

Taking stock of the drug industry, from the lab to the medicine chest

December 8, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Kymera drug positioned to rival Sanofi and Regeneron's Dupixent succeeds in early-stage eczema trial Now, Kymera will aim to show its experimental drug helps patients with eczema and asthma in larger clinical trials. By Jonathan Wosen STAT+ | Driven by GLP-1s, prescription drug spending explodes at major health insurers Some insurers spent more on drugs in nine months this year than they did in all of 2024. Weight loss drugs a major factor, a STAT analysis finds. By Bob Herman STAT+ | Results in Terns leukemia drug study suggest it could be a successor to Novartis blockbuster Terns leukemia drug results presented at ASH suggest it could be a successor to Novartis' blockbuster Scemblix. By Adam Feuerstein Dr. Edwin P. Ewing, Jr./CDC STAT+ | Dyne Therapeutics plans to file for approval for next-generation Duchenne drug The drug showed that it could help patients produce a form of a missing protein, with signs that it could also preserve muscle function. By Jason Mast STAT+ | Structure reports promising weight loss outcomes with obesity drug, but side effect questions loom The drug, aleniglipron, came with high rates of nausea and vomiting, as tolerability becomes a differentiating point among obesity medicines. By Elaine Chen STAT+ | Incyte study results suggest a new approach to treating myelofibrosis The data bolster Incyte's efforts to develop a new type of drug for myelofibrosis, and suggest the treatment may help it replace Jakafi. By Adam Feuerstein CNRI/SCIENCE PHOTO LIBRARY STAT+ | New data from Gilead, Arcellx multiple myeloma CAR-T suggest benefit over rival treatment At the American Society of Hematology annual meeting, Gilead and Arcellx reported promising data for their multiple myeloma CAR-T therapy anito-cel. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser